Table I.
Baseline clinicopathological characteristics of patients with glioma and patients providing control tissues.
| TUSC3 expression | |||||
|---|---|---|---|---|---|
| Characteristics | Number | Positive | Negative | Positive rate (%) | P-valuea |
| Control patients | |||||
| Age median (range), years | 46 (26–76) | ||||
| Gender (%) | |||||
| Male | 6 (46.2) | ||||
| Female | 7 (53.8) | ||||
| Patients with glioma | |||||
| Age median (range), years | 43 (14–66) | 0.007 | |||
| <43 | 30 (50.0) | 6 | 24 | 20.0 | |
| ≥43 | 30 (50.0) | 17 | 13 | 56.7 | |
| Gender | 1.000 | ||||
| Male | 35 (58.3) | 12 | 23 | 34.3 | |
| Female | 25 (41.7) | 8 | 17 | 32.0 | |
| Pathological classification | |||||
| Astrocytoma | 38 (63.3) | 18 | 20 | 47.4 | |
| Oligodendroglioma | 6 (10.0) | 5 | 1 | 83.3 | |
| Glioblastoma | 14 (23.4) | 0 | 14 | 0 | |
| Other types | 2 (3.3) | 0 | 2 | 0 | |
| WHO gradeb | |||||
| I | 1 (1.7) | 1 | 0 | 100 | |
| II | 36 (60.0) | 20 | 16 | 55.6 | |
| III | 9 (15.0) | 3 | 6 | 33.3 | |
| IV | 14 (23.3) | 0 | 14 | 0 | |
a
Positive rates of TUSC3 expression were compared by Fisher's exact test
b
WHO grade was evaluated by two 2 independent pathologists from Qianfoshan Hospital (Jinan, China). WHO grade I–II (low-grade) gliomas are well-differentiated, whereas WHO grade III–IV (high-grade) gliomas are undifferentiated or anaplastic. TUSC, tumor suppressor candidate; WHO, World Health Organization.